文献速递产科

托拉塞米预防子痫前期妇女持续性产后高血压:一项随机对照试验

Torsemide for Prevention of Persistent Postpartum Hypertension in Women With Preeclampsia: A Randomized Controlled Trial.
PubMed 文献 · Obstet Gynecol · 2018-01-01

该随机双盲安慰剂对照试验纳入118例子痫前期妇女,产后24小时内分别口服托拉塞米20 mg/d或安慰剂共5天。产后第5天或出院时持续性高血压发生率托拉塞米组44% vs 安慰剂组58%(RR 0.76,95%CI 0.5-1.1),无显著差异;7-10天、6周高血压、严重高血压、住院时间、再入院及不良事件均无差异。

要点

  • 产后5天托拉塞米组持续性高血压44% vs 安慰剂组58%,RR 0.76(95%CI 0.5-1.1),无显著差异。
  • 7-10天及6周高血压、严重高血压、住院时间、再入院和不良事件两组均无差异。
  • 两组均无严重复合发病或死亡病例。

核心结论

  • 在子痫前期妇女中,产后5天托拉塞米疗程对产后高血压发生率无显著影响。

研究设计与样本

  • 随机双盲安慰剂对照试验,2016年8月至2017年9月在一家三级中心纳入118例子痫前期妇女,1:1随机分至口服托拉塞米20 mg/d或安慰剂共5天,按意向治疗分析。

主要发现

  • 托拉塞米组43例(73%)、安慰剂组45例(76%)为子痫前期伴严重特征或慢性高血压合并子痫前期。
  • 持续性产后高血压发生率托拉塞米组44% vs 安慰剂组58%(相对风险0.76,95%CI 0.5-1.1)。
  • 产后7-10天或6周高血压、严重高血压、产后住院时间、因高血压再入院及不良事件均无差异。
  • 无严重复合发病或死亡病例。

关键数值与推荐

  • 主要结局为产后第5天或出院时至少间隔4小时两次测得收缩压≥150 mm Hg或舒张压≥100 mm Hg(或两者兼有)。
  • 假设子痫前期妇女持续性高血压发生率为50%,需118例受试者以检出50%的发生率下降。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: To evaluate whether torsemide reduces the rate of persistent postpartum hypertension in women with preeclampsia. METHODS: We conducted a randomized, double-blind, placebo-controlled trial of women with preeclampsia at a tertiary center from August 2016 to September 2017. Those with gestational hypertension or renal or cardiopulmonary failure were excluded. Within 24 hours of delivery, women were randomized one to one to oral torsemide, 20 mg/d, or placebo, for 5 days. Our primary outcome was blood pressure greater than or equal to 150 mm Hg systolic or 100 mm Hg diastolic (or both) on two occasions at least 4 hours apart by postpartum day 5 or by the time of hospital discharge. Assuming a 50% rate of persistent hypertension in women with preeclampsia, 118 participants were required to detect a 50% rate reduction. Analyses were by intention to treat. RESULTS: From August 2016 to September 2017, 118 women were randomized: 59 were allocated to torsemide and 59 to placebo. Overall, 43 (73%) women in the torsemide and 45 (76%) in the placebo group had either preeclampsia with severe features or preeclampsia superimposed on chronic hypertension. The rate of persistent postpartum hypertension was 44% in the torsemide and 58% in the placebo group (relative risk 0.76, 95% CI 0.5-1.1). No differences were seen in rate of hypertension 7-10 days or 6 weeks postpartum, severe hypertension, length of postpartum hospital stay, readmission for hypertension, or adverse events. There were no cases of severe composite morbidity or deaths. CONCLUSION: In this trial of women with preeclampsia, a 5-day course of postpartum torsemide did not have a significant effect on the rate of postpartum hypertension. CLINICAL TRIAL REGISTRATION: ClinicalTrials.gov, NCT02813551.

来源:Obstet Gynecol,查看原文。版权归原作者所有。

引用

  1. Viteri OA, Alrais MA, Pedroza C, et al. Torsemide for Prevention of Persistent Postpartum Hypertension in Women With Preeclampsia: A Randomized Controlled Trial. Obstet Gynecol. 2018. PMID: 30303905. doi:10.1097/AOG.0000000000002941

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。